Finerenone is different to existing CKD in T2D treatments. It acts by blocking mineralocorticoid receptor (MR) over activation, which is thought to contribute to CKD progression and cardiovascular damage.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/gyLFJOx
0 Comments